Ernexa Therapeutics Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026 with the U.S. Securities and Exchange Commission on November 6, 2026, reporting a net loss of $2,941 thousand for the third quarter and $12,456 thousand for the nine months ended September 30, 2026.

Key Highlights

  • Q3 2026 net loss: $2,941 thousand, compared to $1,240 thousand in Q3 2025, according to the filing.
  • Nine-month net loss: $12,456 thousand for the nine months ended September 30, 2026, versus $12,582 thousand in the comparable 2025 period.
  • Goodwill impairment: The company recorded a $2,044 thousand impairment of goodwill in the nine months ended September 30, 2026, with no such charge in the prior-year period.
  • Cash position: Cash was $5,575 thousand as of September 30, 2026, up from $1,884 thousand at December 31, 2025.
  • Total assets: $7,104 thousand at September 30, 2026, compared to $5,834 thousand at December 31, 2025.
  • Shares outstanding: 1,692,550 shares of common stock outstanding as of November 6, 2026, up from 314 thousand at December 31, 2025.
  • Accumulated deficit: $258,100 thousand as of September 30, 2026, versus $245,636 thousand at December 31, 2025.

Ernexa Therapeutics Q3 2026 Financial Results: Operating Losses and Balance Sheet Changes

According to the filing, Ernexa Therapeutics Inc. (NASDAQ:ERNA), a Delaware-incorporated therapeutics company headquartered in Cambridge, Massachusetts, reported total operating expenses of $2,990 thousand for the three months ended September 30, 2026, compared to $1,993 thousand in the same quarter of 2025. Research and development expenses rose to $1,871 thousand in Q3 2026 from $1,035 thousand in Q3 2025, while general and administrative expenses were $1,119 thousand versus $958 thousand in the prior-year period.

For the nine months ended September 30, 2026, the company disclosed total operating expenses of $12,754 thousand, which included the full $2,044 thousand goodwill impairment charge recorded during the period. Research and development costs for the nine-month period reached $6,578 thousand, up from $3,480 thousand in the nine months ended September 30, 2025. The filing also noted a gain on extinguishment of contingent liability of $41 thousand in the nine-month 2026 period, and interest income, net, of $148 thousand, contributing to total other income of $258 thousand for that period.

On the balance sheet, the company reported total liabilities of $2,753 thousand and total stockholders' equity of $4,351 thousand as of September 30, 2026. Additional paid-in capital stood at $262,442 thousand, up from $248,034 thousand at December 31, 2025, reflecting the significant increase in common shares issued and outstanding from 314 thousand to 1,645 thousand over the same period. The Series A convertible preferred stock, with 156 thousand shares designated and outstanding at both period-end dates, carried a liquidation preference of $156 thousand, as disclosed in the filing.

What Was Disclosed

Ernexa Therapeutics filed its quarterly report covering the period ended September 30, 2026, disclosing a nine-month net loss of $12,456 thousand, a $2,044 thousand goodwill impairment, increased R&D spending, higher cash balances, and a substantially larger share count relative to December 31, 2025.